CURX Curanex Pharmaceuticals Inc

NEUTRAL Impact: 5/10 8-K
Horizon months Filed May 7, 2026 Processed 1mo ago SEC 0001493152-26-021658
8-K context-dependent: Items 8.01
Latest settled — T+20d
CURX ▲ +3.16% at T+20d
NEUTRAL call ✓ call won +3.16% · α vs SPY +0.03% · entry $0.3160 → $0.3260
Next anchor: T+60d in 8w
Last close $0.3050 (close Jun 8) · -3.48% from $0.3160 entry
Entry anchored
May 7, 09:45 AM ET
via Databento tick
T+1d
+2.22%
call +2.22% · α +1.39%
$0.3230
settled 5w ago
T+5d
-0.32%
call -0.32% · α -1.82%
$0.3150
settled 27d ago
T+20d
+3.16%
call +3.16% · α +0.03%
$0.3260
settled 5d ago
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

Curanex Pharmaceuticals received a 180-day extension from Nasdaq until November 2, 2026, to regain compliance with the $1.00 minimum bid price requirement. The company previously failed to meet the initial compliance deadline of May 4, 2026, and plans to consider a reverse stock split if needed to cure the deficiency.

Actionable Insight

Monitor CURX stock price for potential reverse stock split announcement or any catalyst to push price above $1.00 for 10 consecutive days. Delisting risk remains if compliance is not achieved by November 2, 2026.

Key Facts

  • Nasdaq notified Curanex on May 5, 2026, of an additional 180-day compliance period ending November 2, 2026, to regain minimum bid price compliance.
  • The company's stock had a closing bid price below $1.00 for 30 consecutive business days as of November 5, 2025.
  • Curanex intends to cure the deficiency via a reverse stock split if necessary.
  • If compliance is not demonstrated by November 2, 2026, Nasdaq will initiate delisting proceedings.

Financial Impact

No direct financial impact disclosed; delisting risk could impair liquidity and access to capital.

stock pricelisting status

Risk Factors

  • Failure to regain compliance by November 2, 2026, could result in Nasdaq delisting.
  • A reverse stock split may be dilutive in perception and does not address underlying business fundamentals.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-021658
Document: 0001493152-26-021658-index-headers.html0001493152-26-021658
Document: 0001493152-26-021658-index.html0001493152-26-021658
Document: 0001493152-26-021658.txt0001493152-26-021658
5 reports for CURX
Performance horizon
Filters
Rows
Reports for CURX — sortable, filterable
Type Now
May 14, 2026
26d ago
8-K
NEUTRAL ★ 3/10
$0.3130 $0.3280▲ +4.79%▲ +5.51%$0.3050 (−2.56%)
May 14, 2026
26d ago
Press Release
NEUTRAL ★ 3/10
$0.3130 $0.3280▲ +4.79%▲ +5.51%$0.3050 (−2.56%)
May 7, 2026
4w ago
8-K
NEUTRAL ★ 5/10
$0.3160 $0.3150▼ −0.32%▼ −1.82%$0.3050 (−3.48%)
Apr 2, 2026
9w ago
8-K
NEUTRAL ★ 3/10
$0.4900 $0.4640▼ −5.31%▼ −8.93%$0.3050 (−37.76%)
Mar 30, 2026
10w ago
Press Release
NEUTRAL ★ 3/10
$0.5110 $0.4440▼ −13.11%▼ −17.06%$0.3050 (−40.31%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 7h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access